Quality of life with ribociclib abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison

Background: A cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy is recommended as first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC). Quality of life (QoL) is an important endpoint that affec...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Hope S. Rugo, Victoria Harmer, Joyce O’Shaughnessy, Komal Jhaveri, Sara M. Tolaney, Fatima Cardoso, Aditya Bardia, Vikalp Kumar Maheshwari, Sandeep Tripathi, Sina Haftchenary, Purnima Pathak, Peter A. Fasching
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	SAGE Publishing 2023-02-01
Serie:	Therapeutic Advances in Medical Oncology
Länkar:	https://doi.org/10.1177/17588359231152843
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!